NB32

DRUG2 trials

Sponsors

Orexigen Therapeutics, Inc

Conditions

Nicotine DependenceObesityOverweight

Phase 2

A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent

CompletedNCT00563563

Orexigen Therapeutics, IncNicotine Dependence, Obesity, Overweight

Start: 2007-10-31End: 2008-09-30Updated: 2012-11-02

Phase 3

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

TerminatedNCT01601704

Orexigen Therapeutics, IncObesity, Overweight

Start: 2012-06-30End: 2015-08-31Updated: 2017-02-27

Related Papers

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial

UNC Libraries2020-04-1823 citations

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors

JAMA2016-03-08264 citations